Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fulgent Genetics ( (FLGT) ) has issued an announcement.
On March 17, 2026, Fulgent Genetics completed the previously announced acquisitions of Bako Diagnostics and StrataDx, paying a combined cash consideration of about $56.9 million, subject to post-closing adjustments. Through a purchase and sale agreement and an asset purchase agreement, its Inform Diagnostics subsidiary acquired all equity of StrataDx for roughly $13.5 million and substantially all dermatopathology, podiatric pathology, molecular diagnostics and related therapeutic assets of Bako for about $43.4 million, while also assuming a long-term lease for 29,099 square feet of laboratory and office space in Alpharetta, Georgia.
The deals expand Fulgent’s national footprint and specialty pathology capabilities in dermatology and podiatry, reinforcing its laboratory services platform and positioning it more strongly in the dermatology testing market. By integrating Bako’s and StrataDx’s sector-specific expertise and infrastructure, Fulgent is expected to broaden its testing menu and specialist support offerings, which could enhance its competitive standing as it advances its strategy to build a scaled, fully integrated precision medicine business.
The most recent analyst rating on (FLGT) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
The score is held back primarily by weak profitability and a sharp deterioration in cash flow, alongside bearish technicals. These are partly offset by a very strong, low-debt balance sheet and earnings-call guidance that outlines a path to revenue growth via acquisitions, though management expects near-term margin and EPS pressure.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a technology-based precision medicine company with a well-established laboratory services business and a therapeutic development arm focused on oncology. Its lab services include technical testing and physician interpretation, while its drug development platform uses nanoencapsulation and targeted therapies to improve the profile of cancer treatments, supporting its strategy to evolve from diagnostics into a fully integrated precision medicine provider.
Average Trading Volume: 395,103
Technical Sentiment Signal: Sell
Current Market Cap: $466.9M
See more data about FLGT stock on TipRanks’ Stock Analysis page.